论文部分内容阅读
目的探讨诺和灵30R及诺和锐30治疗2型糖尿病的临床效果。方法将我院收治的64例2型糖尿病患者,随机分为对照组和观察组,两组均行包括培训胰岛素注射方法、技巧及配合饮食、运动治疗等系统糖尿病教育。对照组在此基础上采用诺和灵30R治疗,观察组在此基础上采用诺和锐30治疗,比较两组治疗效果及不良反应发生情况。结果观察组血糖达控制标准时间低于对照组,差异有统计学意义(P<0.05)。观察组与对照组治疗前后FPG、2h-PG差异无统计学意义(P>0.05)。观察组胰岛素用量低于对照组,差异有统计学意义(P<0.05)。结论诺和锐30较诺和灵30R控制血糖效果更理想,胰岛素剂量相当,可更好的降低餐后低血糖的发生率,使用方便,值得临床推广应用。
Objective To investigate the clinical effects of Novolin 30R and Novartis 30 in the treatment of type 2 diabetes mellitus. Methods Sixty-four patients with type 2 diabetes mellitus admitted to our hospital were randomly divided into control group and observation group. Both groups included training in insulin injection, skills and system diabetes education with diet and exercise therapy. On the basis of this study, the control group received Novolin 30R treatment. The observation group was treated with Novo-Rui 30 on the basis of this study. The treatment effect and adverse reactions were compared between the two groups. Results The control group had lower blood glucose level than the control group (P <0.05). There were no significant differences in FPG and 2h-PG between the observation group and the control group before and after treatment (P> 0.05). Insulin consumption in observation group was lower than that in control group, the difference was statistically significant (P <0.05). Conclusion Nuo-Ruo-30 30NOL and 30R better control of blood glucose, insulin dose equivalent to better reduce the incidence of postprandial hypoglycemia, easy to use, it is worth promoting the clinical application.